Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further experiments demonstrated that STMN1 mediated intricate crosstalk between HCCs and hepatic stellate cells (HSCs) via triggering the HGF/MET signal pathway.
|
31785057 |
2020 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, murine and human HCC data indicate significant correlations of STMN1 expression with E2F1/TFPD1 and with KPNA2 expression and their association with poor prognosis in HCC patients.
|
31783876 |
2019 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
On the other hand, miR-223 has been identified as one of the most down-regulated miRNAs in HCC, and its expression was shown to be negatively correlated with STMN1 expression.
|
28982915 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This T<sub>3</sub>-mediated suppression of STMN1 supports the theory that T<sub>3</sub> plays an inhibitory role in HCC tumor growth, and suggests that the lack of normal THR function leads to elevated STMN1 expression and malignant growth.
|
27934948 |
2016 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Construction of a hepatocellular carcinoma cell line that stably expresses stathmin with a Ser25 phosphorylation site mutation.
|
26505358 |
2015 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The expressions of stathmin and EF1α gradually increased as multistep hepatocarcinogenesis progressed, showing the highest levels in HCC.
|
24885363 |
2014 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The molecular mechanism of STMN1 upregulation in HCCs remained unclear.
|
22911364 |
2013 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
STMN1 overexpression further identified subgroups of HCC patients with higher tumor recurrence and worse prognosis among HCC patients with early tumor stage (T1) or intermediate histological grades (G2 and G3), both of whom represent the majority of HCC patients receiving primary curative hepatectomy.
|
20232364 |
2010 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Stathmin expression was up-regulated in HCC tissues, especially in metastatic HCC tissues, compared with normal liver, hepatitis and hepatic cirrhosis tissues.
|
20204289 |
2010 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study suggested for the first time that STMN1 might be a major target for GA and GEA in combating HCC.
|
19086098 |
2009 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A substantial reduction in STMN1 protein was further demonstrated upon restoration of miR-223 expression in HCC cell lines.
|
18555017 |
2008 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of stathmin expression by gene-specific short interfering RNA (siRNA) was associated with a significant reduction of MT-dependent cellular functions such as tumor cell viability, proliferation, migration, and increased apoptosis in HCC cells.
|
17663418 |
2007 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin.
|
17596871 |
2007 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Approximately 90% of HCCs harbouring stathmin overexpression with concomitant p53 mutation or osteopontin overexpression exhibited vascular invasion, and hence the lowest 5-year survival, p = 0.00018 and p = 0.0009, respectively.
|
16739096 |
2006 |